Harris Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-12,000
Closed -$732K 173
2025
Q1
$732K Buy
+12,000
New +$699K ﹤0.01% 128
2019
Q3
Sell
-121,824
Closed -$5.53M 131
2019
Q2
$5.53M Sell
121,824
-734,850
-86% -$34.2M 0.01% 116
2019
Q1
$40.9M Sell
856,674
-6,385,692
-88% -$318M 0.08% 94
2018
Q4
$376M Sell
7,242,366
-781,743
-10% -$42M 0.76% 47
2018
Q3
$498M Sell
8,024,109
-388,967
-5% -$23.1M 0.78% 45
2018
Q2
$466M Buy
8,413,076
+7,772,870
+1,214% +$420M 0.75% 44
2018
Q1
$40.5M Buy
640,206
+148,420
+30% +$9.55M 0.07% 100
2017
Q4
$30.1M Buy
491,786
+99,905
+25% +$6.25M 0.05% 102
2017
Q3
$25M Buy
+391,881
New +$22.9M 0.04% 106
2015
Q2
Sell
-14,267
Closed -$920K 141
2015
Q1
$920K Sell
14,267
-2,200
-13% -$138K ﹤0.01% 139
2014
Q4
$972K Buy
16,467
+867
+6% +$48.9K ﹤0.01% 148
2014
Q3
$798K Hold
15,600
﹤0.01% 146
2014
Q2
$757K Sell
15,600
-6,000
-28% -$296K ﹤0.01% 149
2014
Q1
$1.12M Sell
21,600
-8,424
-28% -$448K ﹤0.01% 144
2013
Q4
$1.6M Hold
30,024
﹤0.01% 147
2013
Q3
$1.39M Sell
30,024
-4,701
-14% -$206K ﹤0.01% 143
2013
Q2
$1.55M Buy
+34,725
New +$1.51M ﹤0.01% 147

Other funds holding BMY

Harris Associates's BMY Position: Q2 2025 in Review

Harris Associates sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 12,000 shares — an estimated $732K sold.

Harris Associates first reported a position in BMY in Q2 2013 and held it in 17 quarters. The position peaked at $498M in Q3 2018. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Harris Associates reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • Harris Associates sold 12,000 Bristol-Myers Squibb shares in Q2 2025, an estimated $732K.
  • Harris Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 17 quarters.
  • Harris Associates's Bristol-Myers Squibb position peaked at $498M in Q3 2018.
  • 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Harris Associates's 13F filing for Q2 2025, filed 14 Aug 2025.